Jupiter neurosciences announces $11 million IPO and Nasdaq listing
- Jupiter Neurosciences priced its IPO at $4.00 per share, offering 2,750,000 shares.
- The company expects to raise $11 million in gross proceeds from the offering.
- Funds will support a Phase II trial for JOTROL in Parkinson’s Disease and other strategic initiatives.
- Shares will trade on Nasdaq under the symbol 'JUNS' starting December 3, 2024.
Read more
Cartesian Therapeutics announces positive updated results from Phase 2b trial of Descartes-08 in participants with myasthenia gravis and outlines design of planned Phase 3 trial
- Phase 2b trial of Descartes-08 showed a 5.5-point reduction in MG-ADL at Month 4, with durable responses through Month 12.
- Descartes-08 is an mRNA CAR-T therapy targeting BCMA, designed for outpatient administration without preconditioning chemotherapy.
- Phase 3 AURORA trial to start in 1H2025, assessing MG-ADL improvement in 100 participants with AChR Ab+ MG.
- Descartes-08 has RMAT and Orphan Drug Designation from the FDA for treating myasthenia gravis.
Read more
Sudo Biosciences begins phase 1 trial of brain-penetrant TYK2 inhibitor SUDO-550
- Sudo Biosciences has dosed the first participants in a Phase 1 trial for SUDO-550, a brain-penetrant TYK2 inhibitor.
- The trial will assess the safety, tolerability, and pharmacokinetics of SUDO-550 in healthy volunteers.
- SUDO-550 is designed to treat neuroinflammatory diseases by effectively crossing the blood-brain barrier.
- The company is also advancing SUDO-286, a topical TYK2 inhibitor, in two Phase 1 trials for psoriasis.
Read more
